Stockscreener 앱 받기
1.30
5.11%
-0.07
시간 외 거래:
1.30
전일 마감가:
$1.37
열려 있는:
$1.4
하루 거래량:
1.33M
Relative Volume:
0.43
시가총액:
$148.06M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.7879
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
-2.26%
1개월 성능:
-21.21%
6개월 성능:
-75.61%
1년 성능:
-78.90%
1일 변동 폭
$1.28
$1.40
1주일 범위
$1.26
$1.44
52주 변동 폭
$1.04
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.30 | 148.06M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN
Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World
Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World
Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat
Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis
Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria
Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa
Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada
Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada
Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com
Jane Street Group LLC Sells 69,867 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Geode Capital Management LLC Acquires 10,863 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Stifel Financial Corp Sells 17,391 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Franklin Resources Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Barclays PLC Buys 301,389 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average Target Price from Brokerages - MarketBeat
Redmile Group, LLC Reduces Stake in Fate Therapeutics Inc - GuruFocus.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Director Acquires $668,579.52 in Stock - MarketBeat
Redmile group sells $573,943 in Fate Therapeutics stock By Investing.com - Investing.com South Africa
Redmile group sells $573,943 in Fate Therapeutics stock - Investing.com
State Street Corp Sells 85,715 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics stock hits 52-week low at $1.59 By Investing.com - Investing.com Canada
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $497,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World
Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com
Charles Schwab Investment Management Inc. Has $2.67 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):